Nov 13 (Reuters) - Alpine Immune Sciences Inc ::Alpine Immune Sciences reports corporate update and third quarter 2017 financial results.Q3 revenue $100,000 versus $700,000.Alpine Immune Sciences Inc - company expects to have cash to fund operations into 2020.Alpine Immune Sciences Inc qtrly earnings per share $0.18.
Full Article
July 31 (Reuters) - Alpine Immune Sciences Inc :Frazier Life Sciences reports 15.8 percent stake in Alpine Immune Sciences as of July 24, 2017 - SEC filing.
Full Article
July 25 (Reuters) - Alpine Immune Sciences:Alpine Immune Sciences Inc completes merger with Nivalis Therapeutics Inc.Nivalis Therapeutics Inc - upon completion of merger and financing, Alpine will have approximately $90 million in cash and cash equivalents.Nivalis Therapeutics Inc - combined company changed its name to Alpine Immune Sciences.
Full Article
July 20 (Reuters) - Nivalis Therapeutics Inc :Nivalis Therapeutics - stockholders approved on July 19 reverse stock split of co's common stock, at ratio of 1 new share for every 4 shares outstanding.Nivalis Therapeutics Inc - stockholders approved all of merger-related proposals in special meeting on July 19.
Full Article
May 1 (Reuters) - Nivalis Therapeutics Inc ::Nivalis Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.57.Nivalis Therapeutics -increased loss for quarter due to $3.5 million in restructuring charges and a $2.0 million increase in stock-based compensation expenses.Nivalis Therapeutics -after a review and negotiation with alpine immune sciences, board decided to approve and enter definitive merger agreement with Alpine.Nivalis -Frazier Healthcare Partners, Alpine Bioventures, Orbimed Advisors, will invest combined additional $17 million into alpine immune sciences prior to close.Nivalis -following merger, Alpine shareholders will own about 74 percent of combined co and nivalis shareholders will own about 26 percent of combined co.Nivalis -Mitchell Gold., alpine's executive chairman and ceo , will become chairman and ceo of combined company.Nivalis Therapeutics Inc says following merger, board of directors of combined company will expand to seven seats.
Full Article
April 18 (Reuters) - Nivalis Therapeutics Inc ::Nivalis Therapeutics-on termination of agreement under specified circumstances, Alpine or co may be required to pay other party termination fee of $2.5 million.Nivalis Therapeutics-upon termination of merger agreement,Alpine or co in some circumstances to reimburse other party's expenses to maximum $1 million-sec filing.
Full Article
April 18 (Reuters) - Nivalis Therapeutics Inc : :Nivalis Therapeutics Inc and Alpine Immune Sciences Inc. Agree to combine.Nivalis therapeutics inc - merger will result in a combined company.Nivalis Therapeutics Inc - Alpine will merge with a wholly-owned subsidiary of nivalis in an all-stock transaction.Nivalis Therapeutics-Frazier Healthcare Partners, Alpine Bioventures, Orbimed Advisors to invest additional $17 million into Alpine Immune Sciences.Nivalis Therapeutics Inc - following merger, current alpine shareholders will own approximately 74 percent of combined company.Nivalis Therapeutics Inc - transaction has been approved by board of directors of both companies.Nivalis Therapeutics Inc - upon closing of transaction, name of combined company will become Alpine Immune Sciences Inc.
Full Article
Nivalis Therapeutics Inc : Nivalis Therapeutics reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.50 .Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.
Full Article
Nivalis Therapeutics Inc : Nivalis Therapeutics announces corporate restructuring . Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees . Nivalis Therapeutics Inc - Board of directors has approved a restructuring plan as part of company's initiative to explore strategic alternatives . Says estimates that it will incur cash severance costs of approximately $3 million . Nivalis Therapeutics - Co estimates it will incur cash severance costs of approximately $3 million, which are expected to be paid during first half of 2017 . Nivalis Therapeutics Inc says Congleton will be stepping down from his role as president and chief executive officer effective January 15, 2017 . Says reduction in force is intended to preserve company's cash while it assesses various strategic alternatives . Nivalis Therapeutics - Co currently projects that it will have approximately $45-$47 million of net cash available for potential strategic transaction . Nivalis Therapeutics - Reduction in workforce includes Jon Congleton, president & CEO, and David Rodman, M.D., chief medical officer .Board has appointed Michael Carruthers, co's chief financial officer, as interim president, effective Jan 15, 2017.
Full Article
Nivalis Therapeutics Inc : Q2 loss per share $0.55 . Nivalis therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.
Full Article
Earnings vs. 
Estimates